Hot Flashes Moderate to Severe
Hot Flashes 0302
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Study Length: This study will consist of a screening period and a 52 week treatment period. Safety follow up will occur 3 weeks after the last dose of study drug.
Target Age/Sex: 40 Years to 65 Years , Female
Participants will receive at no cost: Study medication and study related procedures. Subject may also receive a stipend for time/travel related to the study.